The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can we predict responses to CAR T-cell therapies, such as bb2121?

Sep 14, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, about chimeric antigen receptor (CAR) T-cell therapy for MM.

How can we predict responses to CAR T-cell therapies, such as bb2121?

CAR T cells have proven to be an extremely effective therapy, with 73–100% of patients responding to treatment. In recent studies, complete response (CR) rates of 33–86% have been achieved. So the question becomes, can we predict which patients will achieve CR?

While there is no clear method, there is some evidence linking expansion of T cells and response to therapy. In this video, Nikhil Munshi goes in to this association in more detail and discusses the impact of exposure to, and persistence of, CAR T-cells along with the implications of the development of an anti-CAR T-cell immune response.